trial

Improving Care and Reducing Cost Study

NCTId NCT02364544
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 461 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
461 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-04
Primary completion
2015-06
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Relapse Prevention PlanDaily Support WebsiteComputer CBT for voices and paranoiaFOCUSPrescriber Decision Assistant

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
University of Pittsburgh Medical CenterCollaborator
Boston University Charles River CampusCollaborator
Dartmouth-Hitchcock Medical CenterCollaborator

Investigators

1
John M Kane, MDPrincipal Investigator

Sites

8 total
Fort Lauderdale, United StatesLawrenceburg, United StatesGrand Rapids, United StatesKansas City, United StatesSpringfield, United StatesManchester, United StatesAlbuquerque, United StatesEugene, United States

Facts & assertions

4 sourced
Enrollment
461
Phase
NA
Primary Completion Date
2015-06
Status
COMPLETED
relationships
The graph out of here
drug
Relapse Prevention Plan
drug
Daily Support Website
drug
Computer CBT for voices and paranoia
drug
FOCUS
drug
Prescriber Decision Assistant
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
University of Pittsburgh Medical Center
company
Boston University Charles River Campus
company
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
John M Kane, MD
person